Cargando…
Colorectal peritoneal metastases: Optimal management review
The peritoneum is a common site of dissemination for colorrectal cancer, with a poorer prognosis than other sites of metastases. In the last two decades, it has been considered as a locoregional disease progression and treated as such with curative intention treatments. Cytoreductive surgery (CRS) a...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Baishideng Publishing Group Inc
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6658395/ https://www.ncbi.nlm.nih.gov/pubmed/31367152 http://dx.doi.org/10.3748/wjg.v25.i27.3484 |
_version_ | 1783438957510393856 |
---|---|
author | Sánchez-Hidalgo, Juan Manuel Rodríguez-Ortiz, Lidia Arjona-Sánchez, Álvaro Rufián-Peña, Sebastián Casado-Adam, Ángela Cosano-Álvarez, Antonio Briceño-Delgado, Javier |
author_facet | Sánchez-Hidalgo, Juan Manuel Rodríguez-Ortiz, Lidia Arjona-Sánchez, Álvaro Rufián-Peña, Sebastián Casado-Adam, Ángela Cosano-Álvarez, Antonio Briceño-Delgado, Javier |
author_sort | Sánchez-Hidalgo, Juan Manuel |
collection | PubMed |
description | The peritoneum is a common site of dissemination for colorrectal cancer, with a poorer prognosis than other sites of metastases. In the last two decades, it has been considered as a locoregional disease progression and treated as such with curative intention treatments. Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) is the actual reference treatment for these patients as better survival results have been reached as compared to systemic chemotherapy alone, but its therapeutic efficacy is still under debate. Actual guidelines recommend that the management of colorectal cancer with peritoneal metastases should be led by a multidisciplinary team carried out in experienced centers and consider CRS + HIPEC for selected patients. Accumulative evidence in the last three years suggests that this is a curative treatment that may improve patients disease-free survival, decrease the risk of recurrence, and does not increase the risk of treatment-related mortality. In this review we aim to gather the latest results from referral centers and opinions from experts about the effectiveness and feasibility of CRS + HIPEC for treating peritoneal disease from colorectal malignancies. |
format | Online Article Text |
id | pubmed-6658395 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Baishideng Publishing Group Inc |
record_format | MEDLINE/PubMed |
spelling | pubmed-66583952019-07-31 Colorectal peritoneal metastases: Optimal management review Sánchez-Hidalgo, Juan Manuel Rodríguez-Ortiz, Lidia Arjona-Sánchez, Álvaro Rufián-Peña, Sebastián Casado-Adam, Ángela Cosano-Álvarez, Antonio Briceño-Delgado, Javier World J Gastroenterol Opinion Review The peritoneum is a common site of dissemination for colorrectal cancer, with a poorer prognosis than other sites of metastases. In the last two decades, it has been considered as a locoregional disease progression and treated as such with curative intention treatments. Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) is the actual reference treatment for these patients as better survival results have been reached as compared to systemic chemotherapy alone, but its therapeutic efficacy is still under debate. Actual guidelines recommend that the management of colorectal cancer with peritoneal metastases should be led by a multidisciplinary team carried out in experienced centers and consider CRS + HIPEC for selected patients. Accumulative evidence in the last three years suggests that this is a curative treatment that may improve patients disease-free survival, decrease the risk of recurrence, and does not increase the risk of treatment-related mortality. In this review we aim to gather the latest results from referral centers and opinions from experts about the effectiveness and feasibility of CRS + HIPEC for treating peritoneal disease from colorectal malignancies. Baishideng Publishing Group Inc 2019-07-21 2019-07-21 /pmc/articles/PMC6658395/ /pubmed/31367152 http://dx.doi.org/10.3748/wjg.v25.i27.3484 Text en ©The Author(s) 2019. Published by Baishideng Publishing Group Inc. All rights reserved. http://creativecommons.org/licenses/by-nc/4.0/ This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. |
spellingShingle | Opinion Review Sánchez-Hidalgo, Juan Manuel Rodríguez-Ortiz, Lidia Arjona-Sánchez, Álvaro Rufián-Peña, Sebastián Casado-Adam, Ángela Cosano-Álvarez, Antonio Briceño-Delgado, Javier Colorectal peritoneal metastases: Optimal management review |
title | Colorectal peritoneal metastases: Optimal management review |
title_full | Colorectal peritoneal metastases: Optimal management review |
title_fullStr | Colorectal peritoneal metastases: Optimal management review |
title_full_unstemmed | Colorectal peritoneal metastases: Optimal management review |
title_short | Colorectal peritoneal metastases: Optimal management review |
title_sort | colorectal peritoneal metastases: optimal management review |
topic | Opinion Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6658395/ https://www.ncbi.nlm.nih.gov/pubmed/31367152 http://dx.doi.org/10.3748/wjg.v25.i27.3484 |
work_keys_str_mv | AT sanchezhidalgojuanmanuel colorectalperitonealmetastasesoptimalmanagementreview AT rodriguezortizlidia colorectalperitonealmetastasesoptimalmanagementreview AT arjonasanchezalvaro colorectalperitonealmetastasesoptimalmanagementreview AT rufianpenasebastian colorectalperitonealmetastasesoptimalmanagementreview AT casadoadamangela colorectalperitonealmetastasesoptimalmanagementreview AT cosanoalvarezantonio colorectalperitonealmetastasesoptimalmanagementreview AT bricenodelgadojavier colorectalperitonealmetastasesoptimalmanagementreview |